Aignostics is an AI-powered precision diagnostics and digital pathology company focused on transforming complex biomedical data into actionable insights for precision medicine. The company’s mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine. Aignostics operates as a spin-off from Charité Berlin, with cross-functional expertise spanning data science, machine learning, pathology, and biology, and it supports drug discovery, translational research, clinical trials, and CDx development through collaborations with biopharma partners.
On its website, Aignostics describes access to pathology samples and multimodal data from over 30M patients at leading university hospitals and laboratories, and highlights its development of foundation models and application series for pathology workflows. Its offering includes products such as Foundation Models and the Atlas H&E-TME tumor microenvironment profiling application, as well as services spanning target & biomarker discovery, translational research, and digital diagnostics. The company also states it is ISO 13485 and 27001 certified and has a GCP-ready clinical trial platform.